Skip to main content

Amgen, Syapse Collaborate on Precision Oncology

NEW YORK (GenomeWeb) – Amgen and Syapse have agreed to collaborate in precision oncology, working together to develop observational research analytics tools to assess treatment outcomes and address "areas of unmet need" in cancer care, the companies said Wednesday.

Together, the companies will scan the Syapse Learning Health Network — a data-sharing network for precision oncology — to identify candidates for Amgen-sponsored clinical trials. They also will seek to extend such trials to community health centers.

Thousand Oaks, California-based Amgen also will team with Syapse to develop evidence standards to help accelerate the process of bringing new therapies to market. The Syapse Network provides real-world evidence that can support drug and biotech filings to regulatory authorities, according to the San Francisco-based informatics vendor.

"Our collaboration with Syapse supports this [speeding up of therapy development] effort by leveraging real-world evidence to accelerate bringing new oncology treatments to market and empowers healthcare providers with more robust insights and decision-making tools to improve patient care," Mike Nohaile, Amgen senior vice president of strategy, commercialization, and innovation, said in a statement.

"Through this collaboration and the strategic relationships we've built with community health systems globally, we aim to develop evidence of clinical utility that can be used to bring molecularly targeted treatments to market more quickly and ensure more diverse groups of patients can access them," added Syapse CEO Ken Tarkoff.